Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pCMV-S2.S
- Development stage
- Phase 2
- Modality
- DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics, Gene Therapies
- Administration
- Intramuscular
01
Overview
pCMV-S2.S is a plasmid DNA construct designed for use as a DNA vaccine, primarily investigated for Hepatitis B virus (HBV). The 'pCMV' component refers to the cytomegalovirus promoter, which drives the expression of the inserted gene. The 'S2.S' component likely encodes the pre-S2 and S gene products of the Hepatitis B virus surface antigen (HBsAg), aiming to elicit an immune response against HBV. This construct is utilized in research settings to study immune responses and potential vaccine efficacy.
- Other names
- pCMV-S2.S DNApCMV-S-2.S DNApCMV-S 2.S DNA
02
Targets
HBsAg (Hepatitis B surface antigen)
Beyond the preview
Go deeper on pCMV-S2.S.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pCMV-S2.S.